GSK CEO Emma Walmsley Files Initial Shareholding Notification

TL;DR

GSK CEO Walmsley filed initial shareholding notice on Oct 17.

AI Summary

On October 17, 2024, GSK plc filed a Form 6-K reporting a transaction notification from Emma Walmsley, the Chief Executive Officer. This filing is an initial notification regarding her shareholding.

Why It Matters

This filing provides transparency into the shareholdings of key executives, which can be an indicator of management's confidence in the company's future performance.

Risk Assessment

Risk Level: low — This is a routine disclosure of executive shareholding and does not indicate any new material risks for the company.

Key Players & Entities

• GSK plc (company) — Registrant
• Emma Walmsley (person) — Chief Executive Officer
• October 2024 (date) — Reporting period
• October 17, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $39.2100 — Volume(s)       $39.2100 431       &#xA

Filing Documents

• a6194i.htm (6-K) — 628KB
• 0001654954-24-013064.txt ( ) — 629KB

From the Filing

SHAREHOLDING a6194i   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of October 2024   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       GSK plc   (the  ' Company ')   Transaction notification   1. Details of PDMR/person closely associated with them ('PCA')   a) Name Emma Walmsley   b) Position/status Chief Executive Officer   c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor   a) Name GSK plc   b) LEI 5493000HZTVUYLO1D793   3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted   a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63   b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan   c) Price(s) and volume(s)   Price(s) Volume(s)       £15.0500   797     £15.0500   1,324     £15.0500   1,497             d) Aggregated information     Aggregated volume   Price   3,618   £15.0500   e) Date of the transaction 2024-10-15   f) Place of the transaction   London Stock Exchange (XLON)     1. Details of PDMR/person closely associated with them ('PCA')   a) Name Dr Hal Barron   b) Position/status Non-Executive Director   c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor   a) Name GSK plc   b) LEI 5493000HZTVUYLO1D793   3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted   a) Description of the financial instrument American Depositary Shares ('ADSs')   ISIN: US37733W2044   b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 10 October 2024 on ADSs held in the Company's Deferred Annual Bonus Plan   c) Price(s) and volume(s)   Price(s) Volume(s)       $39.2100 431                     d) Aggregated information N/A (single transaction)   Aggregated volume   Price     e) Date of the transaction 2024-10-15   f) Place of the transaction   New York Stock Exchange (XNYS)     1. Details of PDMR/person closely associated with them ('PCA')   a) Name Julie Brown   b) Position/status Chief Financial Officer   c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor   a) Name GSK plc   b) LEI 5493000HZTVUYLO1D793   3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted   a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')   ISIN: GB00BN7SWP63   b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan   c) Price(s) and volume(s)   Price(s) Volume(

View Full Filing

View this 6-K filing on SEC EDGAR